Webinar
CMC struggles in CGTs: Why manufacturing and quality are critical to meeting FDA expectations
Recent FDA rejections of high-profile cell and gene programs underscore how CMC issues continue to be a leading barrier to approval in advanced therapy development. Learn from Cencora experts and CGT industry leaders about how proactive and strategic planning can help you get ahead of CMC roadblocks.
Key Takeaways
- Flag the most common CMC issues cited in recent Complete Response Letters (CRLs)
- Spot subtle gaps that can derail your BLA submission
- Build a stronger, more proactive CMC strategy
- Better align your processes with FDA expectations to improve your chances of approval
Access the recording
Connect with our cell and gene experts
Our tailored solutions address the unique challenges of advanced therapies, from early discovery through to patient delivery, ensuring that innovative treatments reach those who need them most. Connect with our expert team today to learn how Cencora can support your product’s journey.
